<table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="tbl1" position="float"><object-id pub-id-type="doi">10.7554/eLife.00747.007</object-id><label>Table 1.</label><caption><p>Probability of treatment failure for combination therapy in patients</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.00747.007">http://dx.doi.org/10.7554/eLife.00747.007</ext-link></p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Patient</th><th rowspan="2">Primary tumor type</th><th rowspan="2">Number of metastases</th><th rowspan="2">Total tumor burden (number of cells)</th><th align="center" colspan="3">Probability of treatment failure</th></tr><tr><th>Monotherapy</th><th>Dual therapy: n<sub>12</sub> = 1</th><th>Dual therapy: n<sub>12</sub> = 0</th></tr></thead><tbody><tr><td>N1</td><td>Pancreas</td><td align="char" char=".">18</td><td>2.6 &#215; 10<sup>11</sup></td><td align="char" char=".">1</td><td align="char" char=".">1</td><td align="char" char=".">0.283</td></tr><tr><td>N2</td><td>Colon</td><td align="char" char=".">25</td><td>2.3 &#215; 10<sup>11</sup></td><td align="char" char=".">1</td><td align="char" char=".">1</td><td align="char" char=".">0.26</td></tr><tr><td>N3</td><td>Melanoma</td><td align="char" char=".">26</td><td>1.7 &#215; 10<sup>11</sup></td><td align="char" char=".">1</td><td align="char" char=".">1</td><td align="char" char=".">0.203</td></tr><tr><td>N4</td><td>Melanoma</td><td align="char" char=".">30</td><td>1.4 &#215; 10<sup>11</sup></td><td align="char" char=".">1</td><td align="char" char=".">1</td><td align="char" char=".">0.172</td></tr><tr><td>N5</td><td>Colon</td><td align="char" char=".">21</td><td>1.0 &#215; 10<sup>11</sup></td><td align="char" char=".">1</td><td align="char" char=".">1</td><td align="char" char=".">0.128</td></tr><tr><td>N6</td><td>Melanoma</td><td align="char" char=".">8</td><td>9.8 &#215; 10<sup>10</sup></td><td align="char" char=".">1</td><td align="char" char=".">1</td><td align="char" char=".">0.12</td></tr><tr><td>N7</td><td>Colon</td><td align="char" char=".">25</td><td>9.1 &#215; 10<sup>10</sup></td><td align="char" char=".">1</td><td align="char" char=".">1</td><td align="char" char=".">0.112</td></tr><tr><td>N8</td><td>Pancreas</td><td align="char" char=".">8</td><td>7.4 &#215; 10<sup>10</sup></td><td align="char" char=".">1</td><td align="char" char=".">1</td><td align="char" char=".">0.092</td></tr><tr><td>N9</td><td>Pancreas</td><td align="char" char=".">23</td><td>6.4 &#215; 10<sup>10</sup></td><td align="char" char=".">1</td><td align="char" char=".">1</td><td align="char" char=".">0.08</td></tr><tr><td>N10</td><td>Pancreas</td><td align="char" char=".">5</td><td>5.5 &#215; 10<sup>10</sup></td><td align="char" char=".">1</td><td align="char" char=".">1</td><td align="char" char=".">0.069</td></tr><tr><td>N11</td><td>Colon</td><td align="char" char=".">14</td><td>5.4 &#215; 10<sup>10</sup></td><td align="char" char=".">1</td><td align="char" char=".">1</td><td align="char" char=".">0.068</td></tr><tr><td>N12</td><td>Rectal</td><td align="char" char=".">23</td><td>4.8 &#215; 10<sup>10</sup></td><td align="char" char=".">1</td><td align="char" char=".">1</td><td align="char" char=".">0.061</td></tr><tr><td>N13</td><td>Melanoma</td><td align="char" char=".">9</td><td>4.1 &#215; 10<sup>10</sup></td><td align="char" char=".">1</td><td align="char" char=".">1</td><td align="char" char=".">0.052</td></tr><tr><td>N14</td><td>Pancreas</td><td align="char" char=".">13</td><td>4.1 &#215; 10<sup>10</sup></td><td align="char" char=".">1</td><td align="char" char=".">1</td><td align="char" char=".">0.051</td></tr><tr><td>N15</td><td>Pancreas</td><td align="char" char=".">8</td><td>3.3 &#215; 10<sup>10</sup></td><td align="char" char=".">1</td><td align="char" char=".">1</td><td align="char" char=".">0.042</td></tr><tr><td>N16</td><td>Melanoma</td><td align="char" char=".">7</td><td>2.2 &#215; 10<sup>10</sup></td><td align="char" char=".">1</td><td align="char" char=".">1</td><td align="char" char=".">0.028</td></tr><tr><td>N17</td><td>Melanoma</td><td align="char" char=".">10</td><td>2.1 &#215; 10<sup>10</sup></td><td align="char" char=".">1</td><td align="char" char=".">1</td><td align="char" char=".">0.027</td></tr><tr><td>N18</td><td>Colon</td><td align="char" char=".">4</td><td>2.0 &#215; 10<sup>10</sup></td><td align="char" char=".">1</td><td align="char" char=".">1</td><td align="char" char=".">0.026</td></tr><tr><td>N19</td><td>Melanoma</td><td align="char" char=".">9</td><td>1.8 &#215; 10<sup>10</sup></td><td align="char" char=".">1</td><td align="char" char=".">1</td><td align="char" char=".">0.023</td></tr><tr><td>N20</td><td>Colon</td><td align="char" char=".">3</td><td>1.6 &#215; 10<sup>9</sup></td><td align="char" char=".">1</td><td align="char" char=".">0.881</td><td align="char" char=".">0.002</td></tr><tr><td>N21</td><td>Melanoma</td><td align="char" char=".">21</td><td>1.3 &#215; 10<sup>9</sup></td><td align="char" char=".">1</td><td align="char" char=".">0.828</td><td align="char" char=".">0.002</td></tr><tr><td>N22</td><td>Pancreas</td><td align="char" char=".">1</td><td>8.5 &#215; 10<sup>8</sup></td><td align="char" char=".">1</td><td align="char" char=".">0.677</td><td align="char" char=".">0.001</td></tr></tbody></table><table-wrap-foot><fn><p>For monotherapy, we assume that 50 point mutations (<italic>n</italic> = 50) can in principle confer resistance to the drug. With dual therapy, we assume that 50 point mutations can in principle confer resistance to each drug individually (<italic>n</italic><sub>1</sub> = <italic>n</italic><sub>2</sub> = 50). Two scenarios are modeled: in the first, there is one mutation that can in principle confer resistance to both drugs (i.e., cross-resistance, <italic>n</italic><sub>12</sub> = 1). In the other case, there are no possible mutations that can confer resistance to both drugs (<italic>n</italic><sub>12</sub> = 0). Parameter values: birth rate, <italic>b</italic> = 0.14, death rate, <italic>d</italic> = 0.13, death rate for sensitive cells during treatment, <italic>d</italic>&#8242; = 0.17, point mutation rate <italic>u</italic> = 10<sup>&#8722;9</sup>.</p></fn><fn><p>Colon: colonic adenocarcinoma; Rectal: rectal adenocarcinoma; Pancreas: pancreatic ductal adenocarcinoma.</p></fn></table-wrap-foot></table-wrap>